<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, July 22, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/4636691/genomic-collaboration-and-licensing-deals-2018?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=ntxqk2&amp;utm_campaign=2309826+-+Genomic+Collaboration+and+Licensing+Deals+Report+2018-2026+%7c+Analyze+720%2b+Genomic+Partnerships+%7c+Access+Contracts+and+Source+Documents&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Genomic Collaboration and Licensing Deals 2018-2026">"Genomic Collaboration and Licensing Deals 2018-2026"</a> has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive and structured analysis of 720+ genomic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market. The definitive benchmark for genomic dealmaking Genomic partnering is driven by large-scale data generation, sequencing technologies, and analytical platforms, with deal structures reflecting access to datasets, discovery capabilities, and precision medicine applications. Establish a clear view of market standards The report enables a precise understanding of how genomic deals are structured in practice, allowing you to: <ul><li>Benchmark comparable transactions with confidence</li><li>Detailed analysis of upfronts, milestones, and royalty structures across relevant deals</li><li>Define realistic market parameters</li><li>Clear insight into how deal terms vary by data scale, technology platform, and partner profile</li><li>Support valuation and structuring decisions with evidence</li><li>Ground internal discussions in real transaction data rather than assumptions</li><li>Understand how leading companies approach dealmaking</li><li>Visibility into partner behaviour and recurring deal structures across a data-intensive and precision-driven landscape</li><li>Full visibility into deal structure and execution</li></ul> Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice. This includes: <ul><li>Rights granted and retained</li><li>Development and commercialization responsibilities</li><li>Financial structures and payment triggers</li><li>Key contractual provisions and protections</li></ul> This level of transparency is critical to understanding how value, risk, and control are allocated within genomic partnerships, particularly where large datasets, long-term data access, and integration into discovery workflows are key considerations. Designed for real-world BD and strategy use The report is widely used to: <ul><li>Structure and benchmark data-driven and genomics-based transactions</li><li>Prepare for negotiations with well-defined market context</li><li>Evaluate platform partnerships and data access opportunities</li><li>Support internal strategy with robust, defensible data</li></ul> What's included? <ul><li>720+ genomic collaboration and licensing deals</li><li>Financial terms, including upfronts, milestones, and royalties where disclosed</li><li>Fully searchable deal directory (by company, platform, and application)</li><li>Direct access to SEC-filed agreements and source documents</li><li>Analysis of deal trends, key transactions, and active dealmakers</li><li>A trusted, evidence-based reference for genomic dealmaking</li></ul> Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how genomic partnerships are structured, negotiated, and valued. Companies Featured <ul><li>10X Genomics</li><li>Abbvie</li><li>Adaptive Biotechnologies</li><li>Agilent Technologies</li><li>Akoya Biosciences</li><li>Alnylam Pharmaceuticals</li><li>Amazon Web Services</li><li>Arbor Biotechnologies</li><li>AstraZeneca</li><li>Beam Therapeutics</li><li>Bio-Rad Laboratories</li><li>Bluebird Bio</li><li>Boehringer Ingelheim</li><li>Caribou Biosciences</li><li>Charles River Laboratories</li><li>CRISPR Therapeutics</li><li>Dana-Farber Cancer Institute</li><li>Deep Genomics</li><li>DNAnexus</li><li>Editas Medicine</li><li>Element Biosciences</li><li>Eli Lilly</li><li>Exact Sciences</li><li>Foundation Medicine</li><li>Freenome</li><li>Genentech</li><li>Gilead Sciences</li><li>Guardant Health</li><li>Illumina</li><li>Intellia Therapeutics</li><li>Invitae</li><li>Jackson Laboratory</li><li>Lonza</li><li>Mammoth Biosciences</li><li>Mayo Clinic</li><li>Merck KGaA</li><li>Microsoft</li><li>Mission Bio</li><li>Moderna</li><li>Natera</li><li>Novartis</li><li>Oxford Nanopore Technologies</li><li>Pacific Biosciences</li><li>Pfizer</li><li>QIAGEN</li><li>Regeneron Pharmaceuticals</li><li>Roche Diagnostics</li><li>Sangamo Therapeutics</li><li>Thermo Fisher Scientific</li><li>Twist Bioscience</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/4636691/genomic-collaboration-and-licensing-deals-2018?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=ntxqk2&amp;utm_campaign=2309826+-+Genomic+Collaboration+and+Licensing+Deals+Report+2018-2026+%7c+Analyze+720%2b+Genomic+Partnerships+%7c+Access+Contracts+and+Source+Documents&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/j4a61u</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MjBmMDU5ZGMtODE4YS00ODkzLWE5MTYtMjVjMTA2ODkzNTU3LTEwMjY3MzctMjAyNi0wNy0yMi1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Genomic Collaboration and Licensing Deals Report 2018-2026 | Analyze 720+ Genomic Partnerships | Access Contracts and Source Documents

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn